Key facts
- This page summarizes Deepika Pakianathan's Form 4/A - Amendment filing for PARDES BIOSCIENCES, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Dec 2021, 15:00.
Deepika Pakianathan - 23 Dec 2021 Form 4/A - Amendment Insider Report for PARDES BIOSCIENCES, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 23 Dec 2021
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 30 Dec 2021, 15:00:26 UTC
- Original report date
- 28 Dec 2021
- Prior SEC filing
- 14 Jun 2021
- Next SEC filing
- 28 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dennis Ryan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Deepika Pakianathan filed Form 4/A - Amendment for PARDES BIOSCIENCES, INC. on 30 Dec 2021.
Change
- Previous filing in this sequence was filed on 14 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PRDS
transaction
Class A Common Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 23 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PRDS
transaction
Derivative
Class B Common Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -30,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 23 Dec 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 30,000
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Deepika Pakianathan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer.
SEC remarks
On December 28, 2021, the reporting person filed a Form 4 which contained a clerical error reporting that the reporting person beneficially owned 52,500 shares of Class B Common Stock of FS Development Corp. II prior to its business combination. In fact, as reported in this Form 4, the reporting person beneficially owned 30,000 shares of Class B Common Stock.